--- title: "Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296546525.md" description: "Abbott Laboratories reported stronger-than-expected fiscal Q2 2026 results and raised its annual profit forecast, driven by robust demand for cancer diagnostics and medical devices. This performance reinforces the investment narrative of its diversified healthcare portfolio. However, risks remain regarding pricing pressure and competition in continuous glucose monitoring. The company partnered with Google Health on its Lingo biowearable to integrate AI-enabled health platforms. Analysts project $60.4 billion revenue by 2029, with fair value estimates ranging from $119 to $151." datetime: "2026-08-20T23:48:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296546525.md) - [en](https://longbridge.com/en/news/296546525.md) - [zh-HK](https://longbridge.com/zh-HK/news/296546525.md) generator: "portal-rs" --- # Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative? - In August 2026, Abbott Laboratories reported stronger-than-expected fiscal Q2 results and raised its annual profit forecast, driven largely by robust demand for cancer diagnostics and medical devices. - This earnings outperformance highlights the importance of Abbott's diversified healthcare portfolio, where diagnostics and devices together underpin both growth and resilience. - Next, we’ll examine how this earnings beat and upgraded profit outlook interact with Abbott’s existing investment narrative and growth assumptions. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. ## Abbott Laboratories Investment Narrative Recap To own Abbott, you need to believe in the durability of its diversified healthcare portfolio, especially diagnostics and medical devices, as core earnings drivers. The Q2 2026 beat and higher profit forecast reinforce that view in the near term, while competition and pricing pressure in continuous glucose monitoring remain a central risk that could blunt the impact of new product wins and partnerships if they do not translate into sustained, profitable demand. The new partnership with Google Health around Abbott’s Lingo biowearable is particularly relevant here, because it directly ties Abbott’s glucose sensing capabilities into a broader AI-enabled health platform. For investors focused on catalysts, this highlights how Abbott is trying to deepen the role of continuous glucose and metabolic monitoring in everyday health decisions, at the same time that reimbursement, pricing and competitive dynamics are front of mind for the diabetes and wearable sensor franchise. However, against this positive backdrop, investors should also be aware that... Read the full narrative on Abbott Laboratories (it's free!) Abbott Laboratories’ narrative projects $60.4 billion revenue and $9.5 billion earnings by 2029. This requires 9.0% yearly revenue growth and an earnings increase of about $4.1 billion from $5.4 billion today. Uncover how Abbott Laboratories' forecasts yield a $119.12 fair value, a 4% upside to its current price. ## Exploring Other Perspectives ABT 1-Year Stock Price Chart Five members of the Simply Wall St Community see Abbott’s fair value between US$119 and US$151, showing a wide span of individual estimates. You can weigh those views against the current concern that pricing pressure and competition in continuous glucose monitoring could limit how much partnerships like Google Health ultimately contribute to Abbott’s performance. Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth just $119.12! ## Decide For Yourself Don't just follow the ticker - dig into the data and build a conviction that's truly your own. - A great starting point for your Abbott Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. - Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance. ## Ready For A Different Approach? Early movers are already taking notice. See the stocks they're targeting before they've flown the coop: - The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. - The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free. - Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [MSFT.US](https://longbridge.com/en/quote/MSFT.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Xcel Wealth Management LLC Cuts Stock Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/296700328.md) - [Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT](https://longbridge.com/en/news/296461096.md) - [Abbott settles appeal over $495 million infant formula verdict](https://longbridge.com/en/news/296386129.md) - [Abbott agrees to $670 million settlement of infant formula cases](https://longbridge.com/en/news/296534956.md) - [Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants | ABT Stock News](https://longbridge.com/en/news/296532468.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**